WallStreetZenWallStreetZen

NASDAQ: CRDF
Cardiff Oncology Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Cardiff Oncology revenue was $683.00k for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $151.0k, down 8.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CRDF annual revenue was $683.0k, with 40% growth year-over-year.

CRDF past revenue growth

How has CRDF's revenue growth performed historically?

Company
39.96%
Industry
437.31%
Market
20.27%
CRDF's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CRDF's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CRDF's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CRDF revenue history

Current Revenue
$683.0k
Current Earnings
-$45.5M
Current Profit Margin
-6,655.2%

Be the first to know when CRDF announces revenue.

CRDF Revenue History By Year

CRDF Yearly RevenueCRDF RevenueCRDF ChangeCRDF Revenue Growth
2024-12-31$683.00k$195.00k+39.96%
2023-12-31$488.00k$102.00k+26.42%
2022-12-31$386.00k$27.00k+7.52%
2021-12-31$359.00k-$7.00k-1.91%
2020-12-31$366.00k$121.37k+49.61%
2019-12-31$244.63k-$133.69k-35.34%
2018-12-31$378.33k-$127.08k-25.14%
2017-12-31$505.40k$124.33k+32.63%
2016-12-31$381.07k$68.26k+21.82%
2015-12-31$312.81k$32.63k+11.65%
2014-12-31$280.18k$20.93k+8.07%
2013-12-31$259.25k-$191.16k-42.44%
2012-12-31$450.40k$192.71k+74.78%
2011-12-31$257.70k-$7.97k-3.00%
2010-12-31$265.67k-$388.33k-59.38%
2009-12-31$653.99kN/AN/A

1 of 2

Cardiff Oncology Revenue FAQ

What was CRDF's revenue last quarter?

On Invalid Date, Cardiff Oncology (NASDAQ: CRDF) reported Q4 2024 revenue of $151.00 thousand up 3.21% year over year. In the same quarter last year, Cardiff Oncology's revenue was $156.00 thousand.

What was Cardiff Oncology's revenue in 2024?

Cardiff Oncology's annual revenue for the twelve months ending Dec 31, 2024 was $683.00 thousand, a 39.96% increase year over year.

How much does Cardiff Oncology make in a day?

Based on Cardiff Oncology annual revenue for the past five years, CRDF makes an average of $1,250.41 per day.

What was Cardiff Oncology's annual revenue growth in the past year?

As of Q2 2025, Cardiff Oncology's revenue has grown 39.96% year over year. This is 397.35 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Cardiff Oncology's revenue in the past year totaled $683.00 thousand.

How much does Cardiff Oncology make in a year?

Cardiff Oncology's revenue by year for the past five years is:
  • Cardiff Oncology's revenue for the twelve months ending Dec 31, 2024 was $683.00 thousand, a 39.96% increase year over year.
  • Cardiff Oncology's annual revenue for Dec 31, 2023 was $488.00 thousand, a 26.42% increase from 2022.
  • Cardiff Oncology's annual revenue for 2022 was $386.00 thousand, a 7.52% increase from 2021.
  • Cardiff Oncology's annual revenue for 2021 was $359.00 thousand, a 1.91% decrease from 2020.
  • Cardiff Oncology's annual revenue for 2020 was $366.00 thousand, a 49.61% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.